# Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma

> **NCT02269085** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 8 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Carfilzomib
- **BEHAVIORAL:** Phone Calls

## Key facts

- **NCT ID:** NCT02269085
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-20
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-05-29
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2019-02-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02269085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02269085, "Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02269085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*